Supernus Pharmaceuticals | SUPN - Selling And Administration Expenses


Supernus Pharmaceuticals reported $118.23M in Selling and Administration Expenses for its fiscal quarter ending in March of 2026.





Selling And Administration Expenses Change Date
Abbott USD 3.27B 138M Mar/2026
ANI Pharmaceuticals USD 73.66M 9.14M Mar/2026
Aurora Cannabis CAD 40.62M 1.17M Dec/2025
Bristol-Myers Squibb USD 1.62B 564M Mar/2026
Canopy Growth CAD 28.9M 636K Dec/2025
Cara Therapeutics USD 2.19M 2.45M Sep/2025
Corcept Therapeutics USD 128.04M 13.3M Mar/2026
Eisai JPY 119.54B 7.82B Mar/2026
Eli Lilly USD 2.93B 198M Mar/2026
Novo Nordisk DKK 13.22B 4.22B Mar/2026
Pacira USD 83.88M 7.99M Mar/2026
Perrigo USD 267.3M 11.4M Mar/2026
Pfizer USD 2.92B 1.16B Mar/2026
Supernus Pharmaceuticals USD 118.23M 4.16M Mar/2026
United Therapeutics USD 156.6M 34M Mar/2026
Xeris Pharmaceuticals USD 42.64M 3.82M Dec/2025